Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

David Hom
Rutgers
Program Manager

David Hom is an epidemiologist and Director of Research Operations in the Center for Emerging Pathogens, Division of Infectious Diseases at Rutgers University-New Jersey Medical School. He serves as Program Manager for the FEND-TB program, working and directing the Operations group at Rutgers, FIND and MUSC, the clinical sites and collaborating partners towards implementation, conduct, logistics, and quality assurance of the proposed diagnostic platform reviews.

He has over 30 years of experience in the conduct and coordination of phase I/II IND clinical trials of TB immunoadjuvants (NIH TB Research Unit), evaluating TB diagnostics (NIAID TB Clinical Diagnostics Research Consortium) in endemic settings, HIV/AIDS (research and treatments for mother-to-child transmission, setting up and conducting Africa’s first phase I vaccine trial), and conducting large scale TB natural history/risk of infection and host and pathogen biomarker discovery studies – at sites in Uganda, South Africa, India, Brazil (ICIDR, TB Research Unit, RePORT India), now extending into multi-regional collaborative initiatives of RePORT International in Brazil, China, India, Indonesia, the Philippines and South Africa.

At Rutgers University, he leads a team of 10 dedicated professionals in clinical study coordination, data capture/management, logistics, specimen banking and pre-and post-award management across ten programs working in ten countries across five continents.

Email